---
title: "Esperion acquired in cash-and-CVR merger transaction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292521304.md"
description: "Esperion was acquired in a cash-and-CVR merger valued at approximately $1.1 billion. Shareholders receive $3.16 per share plus contingent value rights. The deal includes refinancing and restructuring of convertible notes to align with the merged entity. Analysts rate the stock as Hold with a $3.16 target, while AI analysis cites neutral sentiment due to financial fragility offset by buyout progress."
datetime: "2026-07-13T17:24:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292521304.md)
  - [en](https://longbridge.com/en/news/292521304.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292521304.md)
generator: "portal-rs"
---

# Esperion acquired in cash-and-CVR merger transaction

Esperion ( (ESPR) ) has issued an announcement.

On July 13, 2026, Esperion was acquired by a parent company in a cash-and-contingent-value-rights transaction valuing the deal at approximately $1.1 billion, with shareholders receiving $3.16 in cash per share plus one non-transferable contingent value right (CVR) that could pay out a pro rata share of up to $100 million upon achieving specified milestones. In connection with the merger, Esperion amended its 5.75% Convertible Senior Subordinated Notes due 2030 so that each $1,000 principal amount becomes convertible into a fixed cash amount plus CVRs, refinanced its capital structure through a new loan agreement, and fully repaid and terminated its prior credit facility, reshaping obligations to align creditors and equity holders with the merged entity’s future performance.

The most recent analyst rating on (ESPR) stock is a Hold  
 with a $3.16 price target.  
 To see the full list of analyst forecasts on Esperion stock,  
 see the ESPR Stock Forecast page. 

**Spark’s Take on ESPR Stock**

According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.

The score is held back primarily by financial fragility (negative equity and continued negative cash flow) despite improved operating performance. Offsetting this, corporate events are a major positive with shareholder-approved, regulator-cleared buyout progress that increases visibility around value, while technicals are moderately supportive. Valuation remains less favorable due to ongoing net losses and no dividend.

To see Spark’s full report on ESPR stock,  
 click here. 

**More about Esperion**

Esperion is a biopharmaceutical company focused on developing and commercializing therapies, including oral treatments, for lowering cholesterol and reducing cardiovascular risk. The company targets patients with elevated LDL-C who are unable to reach treatment goals with existing options, positioning itself within the cardiometabolic segment of the healthcare industry.

**Average Trading Volume:** 15,600,633

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $819.5M

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)

## Related News & Research

- [Archimed completes take-private of Esperion in deal valued up to $1.1 billion](https://longbridge.com/en/news/292496629.md)
- [Esperion Therapeutics Closes Merger; Sets $100M CVR Plan, Amends 2030 Notes, Replaces Credit Facility](https://longbridge.com/en/news/292494712.md)
- [Esperion stockholders approve merger agreement at special meeting](https://longbridge.com/en/news/292068833.md)
- [Top Esperion Executives Quietly Unload a Wave of Shares](https://longbridge.com/en/news/290261607.md)
- [Esperion clears key U.S. antitrust hurdle for merger](https://longbridge.com/en/news/289966325.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**